Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model

BACKGROUND: Today’s standard treatment of advanced-stage ovarian cancer, including surgery followed by a paclitaxel-platinum-based chemotherapy, is limited in efficacy. Recently, we could show that radioimmunotherapy (RIT) with (177)Lu-labelled anti-L1 cell adhesion molecule (L1CAM) monoclonal antib...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindenblatt, Dennis, Fischer, Eliane, Cohrs, Susan, Schibli, Roger, Grünberg, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452682/
https://www.ncbi.nlm.nih.gov/pubmed/26116117
http://dx.doi.org/10.1186/s13550-014-0054-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452682/
https://www.ncbi.nlm.nih.gov/pubmed/26116117
http://dx.doi.org/10.1186/s13550-014-0054-2

Ejemplares similares